Drug intelligence / Profile preview

cyclosporine + erythropoietin + granulocyte colony-stimulating factor + prednisone

Development stage: Unknown
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous

Overview

cyclosporine + erythropoietin + granulocyte colony-stimulating factor + prednisone is an experimental combination regimen investigated by the M.D. Anderson Cancer Center for the treatment of low-risk myelodysplastic syndromes (MDS). This therapeutic approach, termed 'cytokine-immunotherapy,' combines the immunosuppressive effects of cyclosporine (a calcineurin inhibitor) and prednisone (a corticosteroid) with the hematopoietic stimulatory effects of erythropoietin and granulocyte colony-stimulating factor (G-CSF). The rationale for this combination is based on the hypothesis that immune-mediated suppression of hematopoiesis contributes to bone marrow failure in MDS; by modulating the immune system while simultaneously providing growth factor support, the regimen aims to restore effective blood cell production and improve cytopenias in patients with low-risk disease.

Other names: cyclosporine-M.D. Anderson Cancer Center-myelodysplastic syndromesCytokine-Immunotherapy for Low-Risk MDSCyclosporin A + Erythropoietin + G-CSF + Prednisone

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)Erythropoietin ReceptorCN (Calcineurin)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on cyclosporine + erythropoietin + granulocyte colony-stimulating factor + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporine + erythropoietin + granulocyte colony-stimulating factor + prednisone.

Explore the full profile